SCHEMBL2071897

SCHEMBL2071897

COC(CN1C[C@@H]2C[C@H]1CO2)OC

nearest known ligand 0.33

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 2/20 0.33
KCNQ3 O43525 1/20 0.30
KCNQ2 O43526 1/20 0.30
PDE1B Q01064 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4983910 1.00 PDE10A (0.33) PDE10AKCNQ3KCNQ2PDE1B
SCHEMBL22360169 0.83 TLR7 (0.32) PDE10A
SCHEMBL22360139 0.83 TLR7 (0.32) PDE10A
SCHEMBL24368979 0.80 PIK3CD (0.37) PDE10A
SCHEMBL24820178 0.80 PIK3CD (0.37) PDE10A
SCHEMBL23374669 0.80 PIK3CD (0.37) PDE10A
SCHEMBL4326980 0.77 PDE10A (0.31) PDE10A
SCHEMBL23975685 0.74 ESR1 (0.37) PDE10AKCNQ3KCNQ2PDE1B
SCHEMBL14207964 0.74 ESR1 (0.37) PDE10AKCNQ3KCNQ2PDE1B
SCHEMBL20340914 0.74

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7863281-B2 Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2011-01-04 US disclosed
US-20080103161-A1 BICYCLIC HETEROCYCLES, PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS, THEIR USE AND PROCESSES FOR THE PREPARATION THEREOF HIMMELSBACH FRANK 2008-05-01 US disclosed
US-20050159436-A1 Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2005-07-21 US disclosed
EP-1499619-A1 BICYCLIC HETEROCYCLES, MEDICAMENTS CONTAINING THESE COMPOUNDS, THEIR USE, AND METHOD FOR THE PRODUCTION THEREOF BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2005-01-26 EP disclosed
US-20040044014-A1 Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2004-03-04 US disclosed
WO-2003089439-A1 BICYCLIC HETEROCYCLES, MEDICAMENTS CONTAINING THESE COMPOUNDS, THEIR USE, AND METHOD FOR THE PRODUCTION THEREOF BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2003-10-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050159436-A1 Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof RET, CYP11B1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 PDE10A 302/4885KCNQ3 3101/4885KCNQ2 2980/4885
US-20040044014-A1 Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof CYP11B1, CYP11B2, AR PDE10A 526/4885KCNQ3 3404/4885KCNQ2 3415/4885
US-20080103161-A1 BICYCLIC HETEROCYCLES, PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS, THEIR USE AND PROCESSES FOR THE PREPARATION THEREOF RET, CYP11B1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 PDE10A 302/4885KCNQ3 3101/4885KCNQ2 2980/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.